{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:34:50Z","timestamp":1767828890652,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Non-cardiac surgery for hypertrophic obstructive cardiomyopathy (HOCM) is considered to require meticulous perioperative care. \u03b2-blockers are considered the first-line drugs for patients with HOCM, and they play a key role in preventing cardiovascular complications in perioperative care. The bisoprolol transdermal patch has recently become available in Japan, and it is useful for patients who are unable to take oral medication during perioperative care. The aim of this case series was to assess the hemodynamic features of patients with HOCM who used the bisoprolol transdermal patch during perioperative care for non-cardiac surgery.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Between August 2016 and August 2018, we retrospectively analyzed 10 consecutive cases of HOCM with the patients using the bisoprolol transdermal patch during perioperative care. Hemodynamic and echocardiographic features were evaluated before and after patients were switched from oral bisoprolol to transdermal patch therapy or started transdermal patch therapy as a new \u03b2-blocker medication. In addition, cardiovascular complications (all-cause death, cardiac death, heart failure, ventricular tachycardia, and ventricular fibrillation) during the perioperative period were evaluated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>There was no significant change in the patients\u2019 heart rate, blood pressure, ejection fraction, and pressure gradient in the left ventricle after switching from oral bisoprolol to the transdermal patch therapy. On the other hand, patients who started using the bisoprolol transdermal patch as a new \u00df-blocker medication tended to have a decreased heart rate and pressure gradient thereafter, but there was no significant difference in blood pressure or ejection fraction. No cardiovascular complications occurred during the perioperative period.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We described the utilization of the bisoprolol transdermal patch during perioperative care for non-cardiac surgery in patients with HOCM. We determined that the hemodynamic features of these patients did not change significantly after switching to patch therapy. Further, initiation of the bisoprolol transdermal patch as a new \u00df-blocker medication sufficiently tended to decrease the pressure gradient. This unique approach can be an alternate treatment option for HOCM.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>The registry was registered in the University Hospital Medical Information Network Clinical Trials Registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000041820\">UMIN000036703<\/jats:ext-link>). The date of registration was 10\/5\/2019 and it was \u201cRetrospectively registered\u201d.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12872-019-01274-6","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T11:02:39Z","timestamp":1577703759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bisoprolol transdermal patch for perioperative care of non-cardiac surgery in patients with hypertrophic obstructive cardiomyopathy"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4142-0661","authenticated-orcid":false,"given":"Yoichi","family":"Imori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Sangen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukichi","family":"Tokita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"1274_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0735-1097(99)00039-X","volume":"33","author":"BJ Maron","year":"1999","unstructured":"Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 1999;33:1590\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"1274_CR2","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/j.jtcvs.2011.10.020","volume":"142","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. J Thorac Cardiovasc Surg. 2011;142:e153\u2013203.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1274_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1253\/circj.CJ-66-0122","volume":"80","author":"JCS Joint Working Group","year":"2016","unstructured":"JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy (JCS 2012) - digest version. Circ J. 2016;80:753\u201374.","journal-title":"Circ J"},{"key":"1274_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232\u20139.","journal-title":"Circulation."},{"key":"1274_CR5","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu283","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Authors\/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733\u201379.","journal-title":"Eur Heart J"},{"key":"1274_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/clc.4960290206","volume":"29","author":"H Hreybe","year":"2006","unstructured":"Hreybe H, Zahid M, Sonel A, Good CB, Shaver J, Saba S. Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2006;29:65\u20138.","journal-title":"Clin Cardiol"},{"key":"1274_CR7","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","volume":"21","author":"DM Gilligan","year":"1993","unstructured":"Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;21:1672\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1274_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1253\/circj.CJ-17-0532","volume":"82","author":"SI Momomura","year":"2017","unstructured":"Momomura SI, Saito Y, Yasumura Y, Yamamoto K, Sakata Y, Daimon M, et al. Efficacy and safety of switching from oral bisoprolol to transdermal patch in Japanese patients with chronic heart failure. Circ J. 2017;82:141\u20137.","journal-title":"Circ J"},{"key":"1274_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/jch.12208","volume":"15","author":"H Matsuoka","year":"2013","unstructured":"Matsuoka H, Kuwajima I, Shimada K, Mitamura H, Saruta T. Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study. J Clin Hypertens (Greenwich). 2013;15:806\u201314.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1274_CR10","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.jacc.2007.05.053","volume":"50","author":"TH Park","year":"2007","unstructured":"Park TH, Tayan N, Takeda K, Jeon HK, Quinones MA, Zoghbi WA. Supine bicycle echocardiography improved diagnostic accuracy and physiologic assessment of coronary artery disease with the incorporation of intermediate stages of exercise. J Am Coll Cardiol. 2007;50:1857\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"1274_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"KA Hicks","year":"2015","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology\/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). J Am Coll Cardiol. 2015;66:403\u201369.","journal-title":"J Am Coll Cardiol"},{"key":"1274_CR12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/SLA.0b013e31824b45af","volume":"255","author":"LG Glance","year":"2012","unstructured":"Glance LG, Lustik SJ, Hannan EL, Osler TM, Mukamel DB, Qian F, et al. The surgical mortality probability model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg. 2012;255:696\u2013702.","journal-title":"Ann Surg"},{"key":"1274_CR13","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","volume":"35","author":"SD Kristensen","year":"2014","unstructured":"Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, et al. 2014 ESC\/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383\u2013431.13.","journal-title":"Eur Heart J"},{"key":"1274_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/ALN.0b013e3181b6a79f","volume":"111","author":"MJ London","year":"2009","unstructured":"London MJ. Perioperative beta-blockade, discontinuation, and complications: do you really know it when you see it? Anesthesiology. 2009;111:690\u20134.","journal-title":"Anesthesiology."},{"key":"1274_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/hrt.45.6.637","volume":"45","author":"PJ Ross","year":"1981","unstructured":"Ross PJ, Lewis MJ, Sheridan DJ, Henderson AH. Adrenergic hypersensitivity after beta-blocker withdrawal. Br Heart J. 1981;45:637\u201342.","journal-title":"Br Heart J"},{"key":"1274_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/0002-9149(91)90651-Z","volume":"68","author":"DM Gilligan","year":"1991","unstructured":"Gilligan DM, Chan WL, Stewart R, Oakley CM. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol. 1991;68:766\u201372.","journal-title":"Am J Cardiol"},{"key":"1274_CR17","doi-asserted-by":"publisher","first-page":"e12325","DOI":"10.1111\/1755-5922.12325","volume":"36","author":"A Sairaku","year":"2018","unstructured":"Sairaku A, Nakano Y, Shiode N, Suenari K, Oda N, Ono K, et al. Head-to-head comparison of the heart rate variability between the bisoprolol transdermal patch and bisoprolol fumarate tablet. Cardiovasc Ther. 2018;36:e12325.","journal-title":"Cardiovasc Ther"},{"key":"1274_CR18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261\u20138.","journal-title":"Nat Biotechnol"},{"key":"1274_CR19","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1161\/CIRCULATIONAHA.115.015085","volume":"133","author":"C MacIntyre","year":"2016","unstructured":"MacIntyre C, Lakdawala NK. Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2016;133:1901\u20135.","journal-title":"Circulation."},{"key":"1274_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1378\/chest.93.4.705","volume":"93","author":"M Schwartz","year":"1988","unstructured":"Schwartz M, Michelson EL, Sawin HS, MacVaugh H 3rd. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias. Chest. 1988;93:705\u201311.","journal-title":"Chest."},{"key":"1274_CR21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1253\/circj.CJ-12-1618","volume":"77","author":"R Nagai","year":"2013","unstructured":"Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, et al. Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: comparison of the ultra-short-acting beta1-selective blocker landiolol with digoxin (J-land study). Circ J. 2013;77:908\u201316.","journal-title":"Circ J"},{"key":"1274_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00540-016-2199-9","volume":"30","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Inokuchi R, Hiruma T, Tokunaga K, Doi K, Nakajima S. Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. J Anesth. 2016;30:891\u20134.","journal-title":"J Anesth"},{"key":"1274_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","volume":"67","author":"MS Maron","year":"2016","unstructured":"Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016;67:1399\u2013409.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-019-01274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-019-01274-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-019-01274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:21:54Z","timestamp":1609201314000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-019-01274-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1186\/s12872-019-01274-6","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all patients, and ethical approval was obtained from the review committee of Nippon Medical School (approval no. 28\u201307-615), and the study design conformed to the ethical principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yoichi Imori has the following financial relationships to disclose: honoraria (lecture fees) less than $5,000 from Toa Eiyo, Tokyo, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"316"}}